Skip to main content
SpringerLink
Log in

Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vincenti F (2003) Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol 14(7):1940–1948

    Article  PubMed  Google Scholar 

  2. Prashar R, Venkat KK (2016) Immunosuppression minimization and avoidance protocols: when less is not more. Adv Chronic Kidney Dis 23(5):295–300. https://doi.org/10.1053/j.ackd.2016.09.007

    Article  PubMed  Google Scholar 

  3. Downie ML, Gallibois C, Parekh RS, Noone DG (2017) Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health 37(4):248–258. https://doi.org/10.1080/20469047.2017.1374003

    Article  PubMed  Google Scholar 

  4. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA (2015) Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98(1):19–24. https://doi.org/10.1002/cpt.113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jones TE, Morris RG (2002) Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 41(5):381–388. https://doi.org/10.2165/00003088-200241050-00005

    Article  CAS  PubMed  Google Scholar 

  6. Becker G, Witzke O, Baltes A, Hamar P, Philipp T, Heemann U (1996) Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. Transpl Immunol 4(1):68–71

    Article  CAS  PubMed  Google Scholar 

  7. Tada H, Yanagiwara S, Ito K, Suzuki T (1999) Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. Pharmacol Toxicol 84(6):241–246

    Article  CAS  PubMed  Google Scholar 

  8. Chen JC, Ma P (2001) Mechanism of FK506-induced renal hypoperfusion and its reversion in rats. Acta Pharmacol Sin 22(11):1034–1038

    CAS  PubMed  Google Scholar 

  9. Hardy G, Stanke-Labesque F, Contamin C, Serre-Debeauvais F, Bayle F, Zaoui P, Bessard G (2004) Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report. Eur J Clin Pharmacol 60(8):603–605. https://doi.org/10.1007/s00228-004-0824-2

    Article  PubMed  Google Scholar 

  10. Hebert MF, Lam AY (1999) Diltiazem increases tacrolimus concentrations. Ann Pharmacother 33(6):680–682. https://doi.org/10.1345/aph.18356

    Article  CAS  PubMed  Google Scholar 

  11. Li JL, Wang XD, Chen SY, Liu LS, Fu Q, Chen X, Teng LC, Wang CX, Huang M (2011) Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J 11(4):300–306. https://doi.org/10.1038/tpj.2010.42

    Article  CAS  PubMed  Google Scholar 

  12. Bamoulid J, Staeck O, Halleck F, Khadzhynov D, Brakemeier S, Durr M, Budde K (2015) The need for minimization strategies: current problems of immunosuppression. Transpl Int 28(8):891–900. https://doi.org/10.1111/tri.12553

    Article  CAS  PubMed  Google Scholar 

  13. Flynn JT, Pasko DA (2000) Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 15(3–4):302–316

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the Hospital Pharmacy Foundation of Jiangsu Pharmaceutical Association (A201606 and 2016YX011).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Children’s Hospital of Nanjing Medical University, Nanjing, China

    Jie-Yu Sun, Ya-Hui Hu, Hong-Li Guo, Xia Jing, Ze-Jun Xu, Fang Sun, Hui-Lei Guo, Feng Chen & Jing Xu

  2. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China

    Jie-Yu Sun & Xuan-Sheng Ding

Authors
  1. Jie-Yu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ya-Hui Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-Li Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xia Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ze-Jun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hui-Lei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xuan-Sheng Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Feng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.Y. Sun, Y.H. Hu, and H.L. Guo measured blood tacrolimus concentrations and detected the CYP3A5 genotype. Z.J. Xu, X. Jing, F. Sun, and X.S. Ding involved in counseling on drug therapy. H.L. Guo was responsible for the patients. J.Y. Sun, H.L. Guo, and F. Chen analyzed the data and wrote the manuscript. J. Xu critically revised the manuscript.

Corresponding authors

Correspondence to Feng Chen or Jing Xu.

Ethics declarations

The ethical approval was provided by the IEC of Children’s Hospital Affiliated to Nanjing Medical University. The informed consent was obtained from the children’s parents.

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Jie-Yu Sun is a visiting graduate student from the School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Electronic supplementary material

ESM 1

(DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, JY., Hu, YH., Guo, HL. et al. Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis. Eur J Clin Pharmacol 75, 591–593 (2019). https://doi.org/10.1007/s00228-018-2604-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-018-2604-4

Search

Navigation